Viracta is a clinical-stage precision oncology company in the US, focusing on developing treatments for virus-associated cancers. The company's lead product candidate is an all-oral combination therapy known as Nana-val. This regimen combines Viracta’s proprietary investigational drug, nanatinostat—an orally administered histone deacetylase (HDAC) inhibitor—with the antiviral agent valganciclovir. Nana-val is currently under investigation in multiple ongoing clinical trials. These include a pivotal, global, multicenter, open-label Phase 2 basket trial for treating various subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1), and a multinational, open-label Phase 1b/2 trial aimed at treating EBV+ recurrent or metastatic nasopharyngeal carcinoma and other advanced EBV+ solid tumors.